Invado Pharmaceuticals

Invado Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of cancer treatments by targeting the tumor microenvironment. The company's primary strategy involves the use of IVD-1001, a proprietary formulation of the vasodilator sodium nitroprusside, to increase blood flow and oxygenation within solid tumors. This approach is designed to overcome physical barriers to drug delivery and mitigate hypoxia-induced resistance, thereby sensitizing tumors to chemotherapy and other systemic treatments. Invado is currently advancing IVD-1001 through Phase 1 and Phase 2 clinical trials for various advanced malignancies, including pancreatic and lung cancers.